#Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
And the exclusive focus on compounded injectables means no brand-name options, no oral formulations, and no alternative weight loss medications
Although obese mice are not identical to obese humans, the results are highly suggestive
Do not start, stop, or change any medication without consulting your doctor or pharmacist
Hopes are high: Headlines about blockbuster and game-changer diet drugs emerge alongside grim reports about the obesity epidemic, which affects about 36% of adults in the United States
loved it I seen results and my energy has improved Kim Fast shipping & such an easy convenience
